Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by CONRAD.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Follow-on African Consortium for Tenofovir Studies (FACTS)
United States Agency for International Development (USAID)
Information provided by (Responsible Party):
CONRAD
ClinicalTrials.gov Identifier:
NCT01386294
First received: June 28, 2011
Last updated: June 16, 2014
Last verified: May 2012

June 28, 2011
June 16, 2014
October 2011
August 2014   (final data collection date for primary outcome measure)
  • Effectiveness [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    Incidence of HIV-1 infection: HIV incidence will be determine by detection of HIV antibodies using two HIV rapid tests (of which one will be FDA approved) according to algorithm in protocol. One of the rapid tests will detect both HIV-1 and HIV-2; the other will be specific for HIV-1. All endpoints will be reviewed by an expert committee (the Endpoint Adjudication Committee). In carrying out this review, the Committee will use guidelines prepared by the protocol committee for this purpose and recorded in the Manual of Procedures
  • Safety [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
    Grade 2, 3, and 4 clinical and laboratory adverse events as defined by the DAIDS toxicity table
  • Effectiveness [ Time Frame: 25 months ] [ Designated as safety issue: No ]
    Incidence of HIV-1 infection: HIV incidence will be determine by detection of HIV antibodies using two HIV rapid tests (of which one will be FDA approved) according to algorithm in protocol. One of the rapid tests will detect both HIV-1 and HIV-2; the other will be specific for HIV-1. All endpoints will be reviewed by an expert committee (the Endpoint Adjudication Committee). In carrying out this review, the Committee will use guidelines prepared by the protocol committee for this purpose and recorded in the Manual of Procedures
  • Safety [ Time Frame: 25 months ] [ Designated as safety issue: Yes ]
    Grade 2, 3, and 4 clinical and laboratory adverse events as defined by the DAIDS toxicity table
Complete list of historical versions of study NCT01386294 on ClinicalTrials.gov Archive Site
  • Incidence of HSV-2 infection [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    HSV-2 status will be established at enrollment according to a testing algorithm in the protocol. At product discontinuation samples of all those that were HSV-2 seronegative at enrollment will be tested. To identify and confirm incident HSV-2 infections and the timing of these infections, blood samples that were stored will be tested to determine the earliest equivocal or positive result. These samples will be then be tested by HSV Western blot. Samples positive on HSV Western blot will be deemed to be incident HSV-2 infections.
  • Pregnancy [ Time Frame: 30 months ] [ Designated as safety issue: No ]
    Incidence of pregnancy loss, prematurity, low birth weight, and major and minor congenital anomalies will be determined
  • Gel and condom use [ Time Frame: 30 months ] [ Designated as safety issue: No ]
  • HIV-1 incidence after product withdrawal [ Time Frame: 3 months after product withdrawal ] [ Designated as safety issue: No ]
    HIV testing will be conducted 3 months after product discontinuation and if HIV positive, the last stored sample will be tested to ascertain timing of infection and viral tenofovir resistance testing will be performed
  • Incidence of HSV-2 infection [ Time Frame: 25 months ] [ Designated as safety issue: No ]
    HSV-2 status will be established at enrollment according to a testing algorithm in the protocol. At product discontinuation samples of all those that were HSV-2 seronegative at enrollment will be tested. To identify and confirm incident HSV-2 infections and the timing of these infections, blood samples that were stored will be tested to determine the earliest equivocal or positive result. These samples will be then be tested by HSV Western blot. Samples positive on HSV Western blot will be deemed to be incident HSV-2 infections.
  • Pregnancy [ Time Frame: 25 months ] [ Designated as safety issue: No ]
    Incidence of pregnancy loss, prematurity, low birth weight, and major and minor congenital anomalies will be determined
  • Gel and condom use [ Time Frame: 25 months ] [ Designated as safety issue: No ]
  • HIV-1 incidence after product withdrawal [ Time Frame: 3 months after product withdrawal ] [ Designated as safety issue: No ]
    HIV testing will be conducted 3 months after product discontinuation and if HIV positive, the last stored sample will be tested to ascertain timing of infection and viral tenofovir resistance testing will be performed
Not Provided
Not Provided
 
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection

The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.

This is a phase III, multicenter trial to assess the safety and effectiveness of 1% tenofovir gel, administered vaginally by approximately 2900 sexually active women at high risk for sexually transmitted HIV. Approximately 2600 women aged 18-30 years old will be enrolled to achieve the required number of endpoints to show an effect on HIV-1 infection, while up to 300 additional women aged 31-40 years old will be enrolled to collect more safety information in this age group.

This is an event driven study that plans to randomize seronegative women. Participants will be randomized to a 1:1 ratio to receive 1% tenofovir gel or placebo gel. Each will be asked to insert a dose of the assigned study product within 12 hours prior to a coital event and another dose as soon as possible within 12 hours after a coital event. Participants will be advised to use only two doses of gel in a 24 hour period.

All women will be evaluated for the rates of adverse events and the rate of HIV seroconversion. In addition, the study will evaluate several secondary endpoints that bear directly on potential risks and benefits of vaginal tenofovir gel use.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
HIV Prevention
  • Drug: Tenofovir gel
    Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
  • Drug: Universal placebo gel
    The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
  • Experimental: Tenofovir 1% vaginal gel
    Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
    Intervention: Drug: Tenofovir gel
  • Placebo Comparator: Universal placebo gel
    Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
    Intervention: Drug: Universal placebo gel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2900
Not Provided
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed age 18-40 years (inclusive)
  • Able and willing to provide written informed consent
  • Able and willing to provide adequate locator information for study retention and safety purposes
  • Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening
  • HIV negative on two rapid tests performed by study staff within 30 days of enrolment (see algorithm in Appendix 3).
  • No evidence of glycosuria
  • No evidence of proteinuria greater than trace*
  • No history of pathological bone fractures
  • Have a negative pregnancy test
  • Women currently breastfeeding may be enrolled in the study
  • Agree to use a study-approved effective non-barrier form of contraception
  • Agree to adhere to study visits and procedures
  • Willing to use study gel as advised
  • Not using or taking any of the following groups of medications:

    • Nephrotoxic agents
    • Drugs that slow renal excretion
    • Immune system modulators
    • Other antiretrovirals

Exclusion Criteria:

  • History of adverse reaction to latex.
  • Plans any of the following during the study period

    • To travel away from the study site for more than 30 consecutive days.
    • To relocate away from the study site.
    • To become pregnant.
    • To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.
  • If in the opinion of the examining clinician, is not sexually active
  • Inadequate renal function (serum creatinine greater than 1.5mg/dl and creatinine clearance less than 50ml/min, as estimated using the method of Cockcroft and Gault96 )
  • Grade 3 and above ALT and AST at screening or any clinical sign of liver disease ( e.g. ascites, hepatomegaly, jaundice)
  • Abnormal serum phosphate levels (Grade 3 and above)
  • Has a clinically apparent finding on speculum pelvic examination (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with speculum pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.
  • Received previously or receiving an experimental HIV vaccine
  • Currently participating in another HIV prevention intervention study or participation in any other clinical trial with a biomedical intervention in the last six months
  • Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has been completed.
  • Any clinical evidence of untreated cervical abnormalities
  • Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Female
18 Years to 40 Years
Yes
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT01386294
FACTS 001
Yes
CONRAD
CONRAD
  • Follow-on African Consortium for Tenofovir Studies (FACTS)
  • United States Agency for International Development (USAID)
Not Provided
CONRAD
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP